The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 26, 2025

Filed:

Nov. 28, 2018
Applicant:

Uti Limited Partnership, Calgary, CA;

Inventor:

Pedro Santamaria, Calgary, CA;

Assignee:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/17 (2006.01); A61K 9/14 (2006.01); A61K 33/26 (2006.01); A61K 38/41 (2006.01); A61K 39/00 (2006.01); A61K 47/60 (2017.01); A61P 25/00 (2006.01); A61P 25/28 (2006.01); C07K 14/47 (2006.01); A61K 35/12 (2015.01); C07K 14/74 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1774 (2013.01); A61K 9/143 (2013.01); A61K 33/26 (2013.01); A61K 38/1719 (2013.01); A61K 38/415 (2013.01); A61K 39/0008 (2013.01); A61K 47/60 (2017.08); A61P 25/00 (2018.01); A61P 25/28 (2018.01); C07K 14/4713 (2013.01); A61K 2035/122 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/605 (2013.01);
Abstract

Described herein are methods for treating an autoimmune or inflammatory disease in a patient, comprising administering a composition comprising: a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2, PDC-E2, and PDC-E2for DRB3*0202; PDC-E2, PDC-E2, and PDC-E2for DRB5*0101; PDC-E2, PDC-E2, and PDC-E2for DRB4*0101; and PDC-E2for DRB1*0801; and b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers; wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.


Find Patent Forward Citations

Loading…